摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

4-<3-(benzyloxy)phenyl>butan-2-one | 129649-57-6

中文名称
——
中文别名
——
英文名称
4-<3-(benzyloxy)phenyl>butan-2-one
英文别名
4-(3-(benzyloxy)phenyl)butan-2-one;4-(3-Phenylmethoxyphenyl)butan-2-one
4-<3-(benzyloxy)phenyl>butan-2-one化学式
CAS
129649-57-6
化学式
C17H18O2
mdl
——
分子量
254.329
InChiKey
XKNJPHADGQNWLN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.3
  • 重原子数:
    19
  • 可旋转键数:
    6
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    26.3
  • 氢给体数:
    0
  • 氢受体数:
    2

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    4-<3-(benzyloxy)phenyl>butan-2-onemethyl (naphth-2-yl)diazoacetate氯[三(2,4-二叔丁基苯基)亚磷酸]金双三氟甲烷磺酰亚胺银盐 作用下, 以 二氯甲烷 为溶剂, 以47%的产率得到methyl 6-(benzyloxy)-2-hydroxy-2-methyl-1,2,3,4-tetrahydro-1,2'-binaphthyl-1-carboxylate
    参考文献:
    名称:
    Gold-catalyzed construction of two adjacent quaternary stereocenters via sequential C–H functionalization and aldol annulation
    摘要:
    一种新颖的金催化的分子间C-H官能化和醛缩环化反应,用于构建两个相邻的四季胺中心。
    DOI:
    10.1039/c5cc08880a
  • 作为产物:
    描述:
    参考文献:
    名称:
    The development of a novel series of (quinolin-2-ylmethoxy)phenyl-containing compounds as high-affinity leukotriene receptor antagonists. 3. Structural variation of the acidic side chain to give antagonists of enhanced potency
    摘要:
    This paper is the third in a series outlining the development of orally active sulfido peptide leukotriene antagonists containing a (quinolin-2-ylmethoxy)phenyl moiety. In this work the systematic variation of the acid side chain substituents led to dramatic and reproducible changes in the oral activity of these compounds, presumably due to alterations in their pharmacokinetic properties. The most potent compound identified, 5-[4-[4-(quinolin-2-yl-methoxy)phenyl]-3-methylbutyl]tetrazole (32), represents a convergence of good in vitro antagonist activity and a 3-10-fold improvement in oral potency over the current clinical candidate 2. The new findings from these optimization studies are as follows: oxygen substitution in the acid side chain was not necessary for antagonist activity, in vitro and in vivo activity was enhanced by alkyl or phenyl substitution on the gamma-carbon of the acid side chain of para-substituted (quinolin-2-ylmethoxy)phenyl derivatives, and free rotation about the side chain carbon atom adjacent to the (quinolin-2-ylmethoxy)phenyl ring was required for activity. The lead compound of this report (32) is a competitive inhibitor of [3H]LTD4 binding to receptor membrane purified from guinea pig lung (Ki = 12 +/- 3 nM) and of the spasmogenic activity of LTC4, LTD4, and LTE4 in guinea pig lung strip. Dosed orally in guinea pigs, this compound blocks LTD4-induced bronchoconstriction (ED50 0.8 mg/kg) and antigen-induced systemic anaphylaxis (ED50 = 1.2 mg/kg).
    DOI:
    10.1021/jm00172a024
点击查看最新优质反应信息

文献信息

  • [EN] SUBSTITUTED BIPHENYL GPR40 MODULATORS<br/>[FR] MODULATEURS DU GPR40 À BIPHÉNYLE SUBSTITUÉ
    申请人:AMGEN INC
    公开号:WO2009048527A1
    公开(公告)日:2009-04-16
    The present invention provides compounds useful, for example, for treating metabolic disorders in a subject. Such compounds have the general formula I: where the definitions of the variables are provided herein. The present invention also provides compositions that include, and methods for using, the compounds in preparing medicaments and for treating metabolic disorders such as, for example, type II diabetes.
    本发明提供了一种有用的化合物,例如,用于治疗受试者的代谢紊乱。这些化合物具有一般公式I:其中变量的定义在此处提供。本发明还提供了包括这些化合物的组合物,以及使用这些化合物制备药物和治疗代谢紊乱的方法,例如II型糖尿病。
  • Optically active phenethanolamines, their formulations, use and preparation
    申请人:ELI LILLY AND COMPANY
    公开号:EP0007205A1
    公开(公告)日:1980-01-23
    Compounds of the formula (I): wherein: R1 is hydrogen or fluorine; R2 is hydrogen or hydroxy; R, is hydrogen, hydroxy, fluorine, aminocarbonyl, methylaminocarbonyl, methoxycarbonyl or acetoxy; C and C both are asymmetric carbon atoms having and ** the R absolute stereochemical configuration; with the limitation that at least one of R, and R2 is hydrogen; or pharmaceutically acceptable salts thereof are extremely potent inotropic agents.
    式 (I) 的化合物: 其中 R1 是氢或氟 R2 是氢或羟基 R,是氢、羟基、氟、氨基羰基、甲氨基羰基、甲氧基羰基或乙酰氧基;C 和 C 都是不对称碳原子,具有和 ** 的绝对立体化学构型的不对称碳原子;R, 和 R2 中至少有一个是氢;或其药学上可接受的盐是极强的肌力药剂。
  • GALEMMO, ROBERT A.;JOHNSON, WILLIAM H. (JR);LEARN, KEITH S.;LEE, THOMAS D+, J. MED. CHEM., 33,(1990) N0, C. 2828-2841
    作者:GALEMMO, ROBERT A.、JOHNSON, WILLIAM H. (JR)、LEARN, KEITH S.、LEE, THOMAS D+
    DOI:——
    日期:——
  • SUBSTITUTED BIPHENYL GPR40 MODULATORS
    申请人:Amgen, Inc
    公开号:EP2205548A1
    公开(公告)日:2010-07-14
  • US4647579A
    申请人:——
    公开号:US4647579A
    公开(公告)日:1987-03-03
查看更多